--- title: "Pre-market hot trades in US stocks: Akamai Tech up 14.71% pre-market; Natera up 13.05% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/295200697.md" description: "Akamai Tech pre-market rose 14.71%; Natera pre-market rose 13.05%; Jinxin Tech pre-market rose 140.89%; Big Tree Cloud pre-market rose 74.02%; Doximity pre-market rose 67.86%" datetime: "2026-08-07T08:18:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295200697.md) - [en](https://longbridge.com/en/news/295200697.md) - [zh-HK](https://longbridge.com/zh-HK/news/295200697.md) --- # Pre-market hot trades in US stocks: Akamai Tech up 14.71% pre-market; Natera up 13.05% pre-market **Pre-market Hot Trades in US Stocks** Akamai Technologies is up 14.71% in pre-market trading. Based on recent key news: 1. On August 6, Akamai Technologies reported second-quarter earnings that exceeded analyst expectations, primarily due to stable demand for its security and cloud infrastructure services, driving the stock price up 10.5% in after-hours trading. The company's cloud infrastructure service revenue reached $99 million, a year-on-year increase of 39%. Source: Reuters 2. On August 6, Akamai Technologies' operating cash flow declined, while capital expenditures reached 32% of revenue, highlighting the importance of converting cloud investments into sustainable cash generation. Although liquidity remains ample, these capital uses increased the importance of maintaining operating cash flow. Source: Reuters 3. On August 6, Akamai Technologies announced a new 4-year $600 million robotics commitment, along with a $2.8 billion multi-year cloud infrastructure commitment, which is expected to drive total revenue growth to low double digits by 2027. Source: Reuters Strong demand for cloud services has investors focused on cash flow. Natera is up 13.05% in pre-market trading. Based on recent key news: 1. On August 5, Natera submitted an application to Japan's PMDA seeking to use Signatera as a companion diagnostic for muscle-invasive bladder cancer. This move expands Natera's market presence in Japan, driving the stock price up. 2. On August 6, Natera reported second-quarter revenue of $752.8 million, exceeding market expectations of $660.7 million, demonstrating strong financial performance and further boosting the stock price. 3. On August 6, Natera raised its full-year revenue guidance to $2.85 billion to $2.91 billion, reflecting confidence in future growth and enhancing investor confidence. The biotechnology sector has performed strongly recently, boosting investor confidence. **Top Gainers in Pre-market US Stocks** Jinxin Tech is up 140.89% in pre-market trading. Based on recent key news: 1. On August 5, the launch of Jinxin Tech's ADME-One high-throughput platform is considered a major growth driver. The introduction of this platform may drive the company's future performance growth, resulting in a significant increase in stock price. Source: Zhitong Finance Technology industry innovation drives growth, increasing volatility. Big Tree Cloud is up 74.02% in pre-market trading. There has been no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no\_news Doximity is up 67.86% in pre-market trading. Based on recent key news: 1. On August 6, Doximity reported first-quarter revenue of $156.6 million, exceeding market expectations of $151.7 million. The company also raised its revenue forecast for fiscal year 2027 to $671 million to $681 million, slightly above Wall Street expectations This news drove the stock price to soar 73% in after-hours trading. Source: Reuters 2. On August 6, Doximity's net income for the first quarter was $24.315 million, with adjusted EBITDA of $74.8 million, exceeding market expectations of $69.6 million. Strong financial performance boosted investor confidence, driving the stock price up. Source: Reuters 3. On August 6, Doximity announced that strong adoption of its AI technology has driven clinical and commercial momentum, and the company raised its full-year revenue guidance, reflecting strong demand from pharmaceutical and hospital clients. Source: Reuters AI technology applications drive industry growth, but risks need to be monitored ### Related Stocks - [AKAM.US](https://longbridge.com/en/quote/AKAM.US.md) - [NTRA.US](https://longbridge.com/en/quote/NTRA.US.md) - [NAMI.US](https://longbridge.com/en/quote/NAMI.US.md) - [DSY.US](https://longbridge.com/en/quote/DSY.US.md) - [DOCS.US](https://longbridge.com/en/quote/DOCS.US.md) ## Related News & Research - [HSBC Just Downgraded Akamai Technologies Stock. Here’s Why.](https://longbridge.com/en/news/295681786.md) - [Natera partners with Kupando Therapeutics to use Latitude ctDNA test in Phase 1 skin cancer trial](https://longbridge.com/en/news/295645480.md) - [Akamai Q2 revenue edges past estimates on cloud infrastructure segment strength](https://longbridge.com/en/news/295138299.md) - [Natera Executive Chairman Matthew Rabinowitz reports disposal of 2,000 common shares worth $641,800](https://longbridge.com/en/news/295287722.md) - [NTRA: Record revenue and test volumes, with major regulatory wins and raised 2026 guidance](https://longbridge.com/en/news/295157261.md)